NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022
NRx Pharmaceuticals (Nasdaq: NRXP) announced it will report its year-end 2021 financial results on March 31, 2022, before the market opens. A conference call and webcast will take place on the same day at 8:30 AM ET, providing a clinical and corporate update. Investors can submit questions via email before 4:00 PM ET on March 29, 2022. The call will be accessible via phone or webcast, with a replay available afterwards on the company's website. NRx specializes in treatments for severe conditions, including COVID-19 and bipolar depression.
- None.
- None.
--Company to Host Conference Call March 31, 2022, at 8:30AM ET---
RADNOR, Pa., March 28, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 financial results prior to the market open on March 31, 2022. The company will host a conference call and webcast on March 31, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at egoldstein@lifesciadvisors.com by 4:00 PM Eastern Time on March 29, 2022.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 407-9716 (U.S.), (201) 493-6779 (International) Conference ID: 13728080, or through the webcast link NRx Pharmaceuticals Year End Results Call. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is in several Phase II/III studies including a Phase III trial for Critical COVID-19 patients which is sponsored and managed by the US National Institutes of Health, and a Phase II study funded by the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services. The FDA has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy.
NRx Pharmaceuticals is led by executives and board members who have held senior roles at Lilly, Pfizer, GSK and the US FDA. NRx Pharmaceuticals was co-founded by Prof Jonathan Javitt, MD, MPH, who has held leadership roles in various biotechnology startup companies and been appointed to advisory roles in four U.S. Presidential Administrations. The NRx Pharmaceuticals' board includes Dr. Sherry Glied, former U.S. Assistant Secretary for Health (ASPE), Daniel E. Troy, JD, former Chief Counsel of the U.S. FDA, Chaim Hurvitz, former director of Teva and President of the Teva International Group, and General H.R. McMaster, Ph.D. (US Army, Ret.), the 26th United States National Security Advisor.
Cautionary Note Regarding Forward-Looking Statements
This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.
The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.
CORPORATE CONTACT:
Molly Cogan – Senior Director, Global Communications
mcogan@nrxpharma.com
INVESTOR RELATIONS
Eric Goldstein
Managing Director - LifeSci Advisors
egoldstein@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-year-end-2021-results-on-march-31-2022-301511464.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
When will NRx Pharmaceuticals report its year-end 2021 financial results?
What time is the conference call for NRx Pharmaceuticals' financial results?
How can I submit a question for the NRx Pharmaceuticals conference call?
Where can I listen to the NRx Pharmaceuticals conference call?
What is NRx Pharmaceuticals' focus in drug development?
